Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The GIRAFE phase II trial on MVCT-based "volumes of the day" and "dose of the day" addresses when and how to implement adaptive radiotherapy for locally advanced head and neck cancer.
Esteyrie V, Gleyzolle B, Lusque A, Graff P, Modesto A, Rives M, Lapeyre M, Desrousseaux J, Graulières E, Hangard G, Arnaud FX, Ferrand R, Delord JP, Poublanc M, Mounier M, Filleron T, Laprie A. Esteyrie V, et al. Among authors: graff p. Clin Transl Radiat Oncol. 2019 Mar 9;16:34-39. doi: 10.1016/j.ctro.2019.02.006. eCollection 2019 May. Clin Transl Radiat Oncol. 2019. PMID: 30949592 Free PMC article.
Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy.
Graff P, Lapeyre M, Desandes E, Ortholan C, Bensadoun RJ, Alfonsi M, Maingon P, Giraud P, Bourhis J, Marchesi V, Mège A, Peiffert D. Graff P, et al. Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1309-17. doi: 10.1016/j.ijrobp.2006.11.012. Epub 2007 Feb 7. Int J Radiat Oncol Biol Phys. 2007. PMID: 17289292
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.
Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Bourhis J, et al. Among authors: graff p. Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18. Lancet Oncol. 2012. PMID: 22261362 Clinical Trial.
202 results